CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma

Por Quintás-Cardama, Alfonso
Publicado no Oncotarget (2018)

Molecular biology of bcr-abl1–positive chronic myeloid leukemia

Por Quintás-Cardama, Alfonso, Cortes, Jorge
Publicado em 2009

Bullet ‘Manicure’: Does Lead Prevent Hydroxyurea-induced Cutaneous Toxicity?

Por Falchi, Lorenzo, Quintás-Cardama, Alfonso
Publicado no Jpn J Clin Oncol (2014)

MOLECULAR PATHWAYS: JAK/STAT PATHWAY: MUTATIONS, INHIBITORS, AND RESISTANCE

Por Quintás-Cardama, Alfonso, Verstovsek, Srdan
Publicado no Clin Cancer Res (2013)

The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans

Por Pant, Vinod, Quintás-Cardama, Alfonso, Lozano, Guillermina
Publicado em 2012

ADVANCES AND CONTROVERSIES IN THE DIAGNOSIS, PATHOGENESIS, AND TREATMENT OF SYSTEMIC MASTOCYTOSIS

Por Quintás-Cardama, Alfonso, Jain, Nitin, Verstovsek, Srdan
Publicado no Cancer (2011)

The Changing Mutational Landscape of Acute Myeloid Leukemia and Myelodysplastic Syndrome

Por Larsson, Connie A., Cote, Gilbert, Quintás-Cardama, Alfonso
Publicado em 2013

Investigational Immunotherapeutics for B-Cell Malignancies

Por Quintás-Cardama, Alfonso, Wierda, William, O'Brien, Susan
Publicado no J Clin Oncol (2010)

Monitoring Molecular Response in Chronic Myeloid Leukemia

Por Cortes, Jorge, Quintás-Cardama, Alfonso, Kantarjian, Hagop M.
Publicado no Cancer (2010)

Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia

Por Quintás-Cardama, Alfonso, Han, Xin, Kantarjian, Hagop, Cortes, Jorge
Publicado em 2009

Early Cytogenetic and Molecular Response During First-Line Treatment of Chronic Myeloid Leukemia in Chronic Phase: Long-Term Implications

Por Quintás-Cardama, Alfonso, Cortes, Jorgé E., Kantarjian, Hagop M.
Publicado em 2011

p53 pathway dysfunction in AML: beyond TP53 mutations

Por Post, Sean M., Kornblau, Steven M., Quintás-Cardama, Alfonso
Publicado no Oncotarget (2017)

Prognostic Impact of the MDM2(SNP309) Allele in Leukemia and Lymphoma

Por Post, Sean M., Pant, Vinod, Abbas, Hussein, Quintás-Cardama, Alfonso
Publicado em 2010

Evolution of Therapies for Chronic Myelogenous Leukemia

Por Santos, Fabio P S, Kantarjian, Hagop, Quintás-Cardama, Alfonso, Cortes, Jorge
Publicado em 2011

THE RISE AND FALL OF GAKEKEEPER MUTATIONS? THE BCR-ABL1(T315I) PARADIGM

Por Gibbons, Don L., Pricl, Sabrina, Cortes, Jorge, Quintás-Cardama, Alfonso
Publicado no Cancer (2011)

Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability

Por Pant, Vinod, Xiong, Shunbin, Iwakuma, Tomoo, Quintás-Cardama, Alfonso, Lozano, Guillermina
Publicado em 2011

Prognostic Model to Identify Patients With Myelofibrosis at the Highest Risk of Transformation to Acute Myeloid Leukemia

Por Quintás-Cardama, Alfonso, Kantarjian, Hagop, Pierce, Sherry, Cortes, Jorge, Verstovsek, Srdan
Publicado em 2013

Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis

Por Quintás-Cardama, Alfonso, Sever, Matjaz, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan
Publicado no Leuk Lymphoma (2013)

SIGNIFICANCE OF CYTOGENETIC ABNORMALITIES IN PATIENTS WITH POLYCYTHEMIA VERA

Por Sever, Matjaz, Quintás-Cardama, Alfonso, Pierce, Sherry, Zhou, Lingsha, Kantarjian, Hagop, Verstovsek, Srdan
Publicado em 2013

PREDICTING OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AT ANY TIME DURING TYROSINE KINASE INHIBITOR THERAPY

Por Quintás-Cardama, Alfonso, Choi, Sangbum, Kantarjian, Hagop, Jabbour, Elias, Huang, Xuelin, Cortes, Jorge
Publicado em 2014